Legend Biotech LEGN
Legend Biotech is a biotechnology company developing advanced cell therapies, notably its CAR-T therapy CARVYKTI for the treatment of multiple myeloma, commercialized in collaboration with Johnson & Johnson. Legend Biotech shows exceptional revenue growth of 51.9%, driven by CARVYKTI, but its financial health is fragile with a Net Debt/EBITDA of 16.50 and a negative ROE of -8.08%, reflecting the high investment needed to scale cell therapy.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Legend Biotech is a biotechnology company developing advanced cell therapies, notably its CAR-T therapy CARVYKTI for the treatment of multiple myeloma, commercialized in collaboration with Johnson & Johnson. Legend Biotech shows exceptional revenue growth of 51.9%, driven by CARVYKTI, but its financial health is fragile with a Net Debt/EBITDA of 16.50 and a negative ROE of -8.08%, reflecting the high investment needed to scale cell therapy.
Score by category
| Category | Score |
|---|---|
| Financial health | 3.8 |
| Quality / Moat | 5.1 |
| Valuation | 3.7 |
| Growth | 10.0 |
| Dividend | 1.5 |
| Momentum | 0.3 |
| Risk & Context | 8.2 |
OVERALL SCORE: 5.1/10
Context and risks
The rise in 10-year Treasury yields (5.17%) affects Legend as a high-growth biotech company without profits, by increasing the discount rate on its future cash flows. However, the effect is moderate because its forward P/E of 18.2 does not reflect an extreme growth valuation.
News considered in the analysis
- Legend Names Novartis Executive as CEO — Nombramiento de un ejecutivo de Novartis como CEO; aporta experiencia en comercialización farmacéutica a gran escala, relevante para el lanzamiento de CARVYKTI, pero el impacto en beneficios es indirecto y moderado.
- LEGN’s New CEO From Novartis Paves Way For Buyout Speculation — Especulación sobre una posible adquisición tras el nombramiento del CEO; es un rumor no confirmado, con probabilidad baja de materializarse, pero podría añadir una prima de control a la valoración.
- Legend Biotech (LEGN) Heads To Morgan Stanley Conference, Is The 57% Valuation Gap Justified? — Artículo de análisis sobre la valoración y asistencia a una conferencia; sin información nueva material, es ruido.
- Can Legend Biotech (LEGN) Turn Cell Therapy Scale Into Compounding Wealth? — Artículo de opinión genérico sobre el potencial de la terapia celular; sin información nueva, es ruido.
Verdict: Hold; the growth potential is real, but high leverage and lack of profitability warrant caution until the company demonstrates sustainable margin improvement.
Main risk: The main risk is the extremely high leverage (Net Debt/EBITDA of 16.50) which, combined with a negative ROE, leaves the company vulnerable to tighter financing conditions or delays in the commercialization of CARVYKTI.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →